US investors may prefer to purchase ADRs rather than ordinary shares in Anteris Technologies Ltd’s home market because ADRs trade, clear and settle according to US market conventions. ADRs allow chiefly US investors to diversify into non-US securities, relatively easily.
ANTERIS PRESS RELEASES
ANTERIS PRESS RELEASES
- 2024
- 2023
- 2022
- 2021
- 2020
- 2019-2017 Timeline
- Financial News
Jan 9, 2024
Anteris is pleased to provide a copy of an Investor Update Presentation to be held today at the Annual J.P. Morgan Healthcare Conference.
- Clinical & Program Updates
- Financial News
Oct 25, 2023
Anteris reports 30-day data from the US Early Feasibility Study (EFS) for DurAVR™ Transcatheter Heart Valve (THV). The preliminary results 30 days post-procedure included data from 12 out of the 15 enrolled patients (three patients awaiting scheduling).
Oct 25, 2023
Anteris reports data from its US Early Feasibility Study (EFS) for DurAVR™ Transcatheter Heart Valve (THV), a new class of aortic valve replacement (AVR) and the world’s only biomimetic, single-piece transcatheter aortic valve.
Oct 17, 2023
Anteris reports completing enrolment in its FDA approved Early Feasibility Study (EFS or the Study) in the United States. DurAVR™ THV is a new class of biomimetic valve and the world’s only balloonexpandable, single-piece transcatheter aortic valve. The EFS is an essential step towards receiving FDA clearance in the US for commercialization of this innovative medical technology.
Aug 14, 2023
Anteris Technologies reported today that DurAVR™ THV, a new class of biomimetic valve and the world’s only balloon-expandable, single-piece transcatheter aortic valve, was implanted in a second successful Valve-in-Valve (ViV) procedure as part of Health Canada’s Special Access Program (SAP).
Aug 09, 2023
Anteris Technologies Ltd reported today that DurAVR™ Transcatheter Heart Valve (THV), a new class of aortic valve replacement (AVR) and the world’s only biomimetic, single-piece transcatheter aortic valve, was used to successfully treat patients as part of the DurAVR™ THV Early Feasibility Study (EFS or the Study) in the United States. The EFS is an essential step towards receiving FDA approval in the US and commercialisation of this innovative medical technology.
July 31, 2023
Anteris Technologies Ltd reported today that for the first time, DurAVR™ THV, a new class of biomimetic valve and the world’s only balloon-expandable, single-piece transcatheter aortic valve, was used in a valve-in-valve (ViV) procedure as part of Health Canada’s Special Access Program (SAP).
June 13, 2023
Anteris Technologies Ltd recently presented new patient data at the TVT conference. The results show DurAVR™ THV maintained excellent haemodynamic performance at 30 days, as previously reported with this patient cohort at 48 hours post-procedure.
June 09, 2023
Anteris Technologies Ltd (Anteris or the Company) (ASX: AVR) presents the latest data from the DurAVR™ First-In-Human Study at the TVT Conference. Results show DurAVR™ THV continues to maintain excellent haemodynamic performance as previously reported at one year and 30 day time points.
May 31, 2023
Anteris Technologies Ltd announces DurAVR™ THV delivers exceptional haemodynamic outcomes in a third patient cohort, comprising seven First-in-Human Study participants and one compassionate case, further validating results previously reported.
May 22, 2023
Anteris Technologies Ltd is delighted to announce the publication of “Early safety and feasibility of a first-in-class biomimetic transcatheter aortic valve (DurAVR™)” in EuroIntervention. The publication reports interim results from the DurAVR™ First-in-Human (FIH) Study designed to evaluate the safety and efficacy of the DurAVR™ THV, a first-in-class biomimetic valve, in the treatment of patients with symptomatic severe aortic stenosis.
May 17, 2023
Anteris Technologies Ltd is pleased to announce that the United States Patent and Trademark Office has issued another utility patent to the Company for the novel DurAVR™ transcatheter heart valve (THV).
April 19, 2023
Anteris Technologies Ltd is pleased to announce that the Company has entered an agreement with v2vmedtech, inc. (“Agreement”) to partner with leading physicians to develop an innovative heart valve repair device for the minimally invasive treatment of mitral and tricuspid valve regurgitation (“Devices”) – also known as a leaky valve – a market expected to be $A4.1 Bn by 20281.
April 12, 2023
Anteris Technologies Ltd is pleased to announce that the United States Patent and Trademark Office has issued a utility patent to the Company for the novel DurAVR™ transcatheter heart valve (THV).
Feb 09, 2023
Anteris Technologies Ltd is pleased to announce that the United States Food and Drug Administration (FDA) has granted expanded approval for the DurAVR™ THV System in Subjects with Severe Aortic Stenosis: Early Feasibility Study (EFS).
Jan 16, 2023
Anteris Technologies Ltd is delighted to announce 12-month results from the DurAVR™ First-in-Human (FIH) Study designed to evaluate the safety and efficacy of the DurAVR™ THV in patients with symptomatic severe aortic stenosis.
Oct 26, 2023
Anteris has raised $40 million with the issue of two million new ordinary shares (New Shares) at $20 per New Share (Placement). The funds will be used for preparation for the FDA Pivotal trial of the Company’s DurAVR™ THV for treating severe aortic stenosis, continued Valve-in-Valve trials and general working capital expenses.
Sep 12, 2023
Anteris Technologies announced today that Wayne Paterson, the Chief Executive Officer of Anteris will present at the Cantor Fitzgerald Annual Global Healthcare Conference in New York, NY on Tuesday, September 26, 2023, at 2:45 p.m. Eastern Time.
Aug 09, 2023
Anteris Technologies Ltd (ASX: AVR) (“Anteris” or the “Company”) announced today that it has established a sponsored Level 1 American Depository Receipt (ADR) program in the United States. The ADR program has been set up to improve U.S. investor access to Anteris ordinary shares.
The ADRs representing Anteris ordinary shares will trade on the over-the-counter (OTC) market with the ticker symbol ANTTY. Deutsche Bank has been appointed as the Depositary Bank for Anteris Technologies’ ADR program.
May 29, 2023
Anteris Technologies Ltd is pleased to provide the attached Chairman’s Address and Chief Executive Officer Presentation to the Annual General Meeting being held today.
Feb 09, 2023
Anteris Technologies Ltd has placed 1.458 million new ordinary shares in the Company (New Shares) to various sophisticated and professional investors at an issue price of $24.00 per New Share1, raising $35 million (Placement).
Feb 09, 2023
Anteris Technologies Ltd is pleased to announce that the Company has entered into a non-binding agreement with Yorkville Advisors Global, LP (Investor) to provide a $50 million SEPA facility to Anteris.
- Clinical & Program Updates
- Financial News
Sep 19, 2022
Anteris Technologies Ltd presents preliminary results demonstrating for the first-time restoration of normal pre-disease blood flow after aortic valve replacement at Transcatheter Cardiovascular Therapeutics (TCT) conference, the world's foremost meeting of interventional cardiologists.
July 11, 2022
Anteris Technologies Ltd reports the 30-day follow-up results on the second cohort of (eight) patients showed clinically significant improvements.
June 21, 2022
Anteris Technologies Ltd is pleased to announce the 6 month follow up of our first cohort of 5 patients. The 6 month follow up is informal (formal follow ups according to the study protocol are 30 days and 1 year). All patients are doing very well and in fact have shown marked improvements since the 3 month follow up.
May 31, 2022
Anteris Technologies Ltd reports eight more patients were successfully treated last week, as part of the ongoing first-in-human DurAVR™ THV study conducted at the Tbilisi Heart and Vascular Clinic, Tbilisi, Georgia.
May 25, 2022
As outlined by Mr Wayne Paterson, Chief Executive Officer at the Annual General Meeting, Anteris Technologies Ltd (the Company) is pleased to announce that we have commenced treating the second cohort of patients as part of the first-in-human study for the Company’s DurAVR™ transcatheter heart valve system.
Jan 24, 2022
Anteris Technologies Ltd reports the first-in-human DurAVR™ THV study met or exceeded its interim study objectives.
Mar 22, 2022
Anteris Technologies Ltd announces the Company has entered a binding agreement to place 1,840,000 new Ordinary Shares (New Shares) raising USD 20 million ($A 28 million) to Perceptive Life Sciences Master Fund, Ltd and managed by Perceptive Advisors (Perceptive) at $A15 a share, representing a 20% discount to the closing price on 28 February 2022.
Feb 08, 2022
Anteris Technologies Ltd announces that it has received a confidential, non-binding proposal to negotiate a letter of intent, which letter sets out a proposal to merge with NASDAQ-listed special purpose acquisition company Medicus Sciences Acquisition Corp. (MSAC). MSAC currently has no commercial operations and was established as a blank cheque company for the purpose of, amongst other things, effecting a merger, share exchange or business combination with one or more businesses.
- Clinical & Program Updates
- Financial News
Nov 22, 2021
Anteris Technologies Ltd reports successfully implanting five TAVR patients during the week of 14 November 2021 in a first-in-human (FIH) study to assess the DurAVR™ THV system for treating severe aortic stenosis. The study was carried out at the Tbilisi Heart and Vascular Clinic, Tbilisi, Georgia.
Apr 27, 2021
Anteris Technologies Ltd reports reaching concept lock on critical components of its ComASUR™ Transfemoral Delivery System. Most importantly, the novel commissural alignment component which gives the physician the ability to align the commissures of the replacement valve to the native valve is now fully functional. This aspect of Transcatheter Aortic Valve Replacement (TAVR)
Mar 29, 2021
Anteris Technologies Ltd reports results from the Company’s anti-calcification study indicating its ADAPT® treated tissue has superior anti-calcification attributes compared with tissues used in competitor valves.
Oct 27, 2021
Anteris Technologies Ltd has placed 625,000 new Ordinary Shares (New Shares) to funds managed or advised by Melbourne-based global investor L1 Capital (Investors), including L1 Long Short Fund Limited, at $8.00 each raising $5 million. The placement price represents a 5% discount to the closing spot price.
Aug 02, 2021
Anteris Technologies Ltd is pleased to announce the placement of 1.125m new Ordinary shares (New Shares) to sophisticated investors at $8.00 per share raising a total $9 million. The proceeds of the Placement will be used for working capital predominantly related to the development of DurAVR™TM, the Company’s 3D single-piece aortic valve for the treatment of Aortic Stenosis.
Jan 20, 2021
Anteris Technologies Ltd announces that the first tranche closing under the convertible security and share purchase agreement to Mercer Street Global Opportunity Fund, LLC (Mercer), as announced to ASX on 6 January 2021, has occurred today, raising $2.5M before costs.
Jan 06, 2021
Anteris Technologies Ltd announces a funding package of up to $20M including $2.5M to be initially drawn down upon completion of the conditions precedent (see further details below). The funding provides additional working capital as Anteris advances the development of DurAVR™, its 3D single-piece aortic valve for the treatment of aortic stenosis.
- Clinical & Program Updates
- Financial News
Nov 23, 2020
Anteris Technologies Ltd is pleased to advise that its 3D single-piece aortic valve DurAVR™ has been selected as a “Best Innovation” at the PCR London Valves 2020 virtual conference, with data from the company’s first-in-human trial to be presented.
Nov 10, 2020
Anteris Technologies Ltd reports interim results from the Company’s anti-calcification study indicating its ADAPT® treated tissue has superior anti-calcification attributes compared with tissues used in competitor valves.
Sep 08, 2020
Anteris Technologies Ltd a structural heart company advancing the DurAVR™ valve, a novel single-piece 3D aortic valve replacement solution, has been granted a patent in the United States for the sterilisation method employed in the manufacture of the Company’s ADAPT® tissue.
Mar 27, 2020
Admedus Limited announces the first implantation of its ADAPT® treated single-piece 3D aortic valve in a patient with aortic stenosis.
Jan 22, 2020
Admedus Limited announces approval for first-in-human surgical aortic valve replacement (SAVR) trial of its proprietary ADAPT® single-piece 3D aortic valve at the Leuven University Hospitals. The UZ Leuven Medical Ethics Committee approved the clinical trial protocol.
Dec 30, 2020
Anteris Technologies Ltd, a structural heart company advancing the DurAVR™ valve, a novel single-piece 3D aortic valve replacement solution, is pleased to announce the successful completion of a placement of 316,954 fully paid Ordinary Shares at $3.37 per new share, raising a total of $1.1m.
AMERICAN DEPOSITARY RECEIPT (ADR) PROGRAM FAQS
AMERICAN DEPOSITARY RECEIPT (ADR) PROGRAM FAQS
Anteris Technologies Ltd has established a sponsored Level 1 American Depository Receipt (ADR) program in the United States. The ADRs representing Anteris ordinary shares will trade on the over-the-counter (OTC) market with the ticker symbol ANTTY. Deutsche Bank has been appointed as the Depositary Bank for Anteris Technologies’ ADR program.
Set out below is a series of Frequently Asked Questions in relation to this program.
An ADR is a negotiable US dollar denominated certificate representing ownership of share(s) in a non-US company. Anteris Technologies Ltd ADRs represent Anteris Technologies Ltd ordinary shares deposited with the depositary bank, to underlie such certificates and carry the rights attached to them as detailed in the Depositary Agreement. Holders of ADRs receive dividends in US dollars (if applicable) and have the right to vote on shareholders resolutions (if applicable). The term ADR and ADS are often used interchangeably. ADRs were specifically designed to facilitate the purchase, holding and sale of non-US securities by US investors.
The ADR ratio defines the numeric relationship between the number of ADRs and the number of ordinary shares. Every 1 ordinary Anteris Technologies Ltd share represents 1 Anteris Technologies Ltd ADR.
Anteris Technologies Ltd established the ADR program to make it easier for US investors to invest in Anteris Technologies Ltd. ADRs are easier for US investors for various reasons including that administrative costs are reduced and capital gains are realized in US dollars.
We hope that the ADR program encourages US investors to increase their exposure to Anteris Technologies Ltd, as it will now be easier for them to do so.
ADR issuers are typically large corporations with primary listings outside of the US. Any non-US company seeking to raise capital in the US or increase their base of US investor can also issue ADRs.
Anteris Technologies Ltd ADRs are traded over-the-counter (OTC) on the electronic market operated by OTCMarkets. For more information, visit www.otcmarkets.com
The OTC Markets is a decentralized market for securities that are not listed on a stock exchange. Trading on OTC Markets occurs via a network of dealers who carry inventories of securities to facilitate the buy and sell orders of investors.
Deutsche Bank Trust Company Americas is the depositary bank for Anteris Technologies Ltd’s ADR program. The depositary bank plays a key role in issuance as well as cancellation of ADRs. It also maintains the ADR holder register, distributes the dividends in US dollars (if applicable) and facilitates the exercise by the ADRs holders of their voting rights (if applicable).
Anteris Technologies Ltd ADRs are denominated in US dollars.
A registered holder is the party whose name appears on the books of the depositary bank. The registered holder is considered the owner of record. A beneficial holder is the ultimate owner of the security, whose holdings are registered in a name other than their own, such as in the name of a broker, bank or nominee.
Converting ordinary shares into ADRs must be done through a broker investment advisor or for registered holders through Deutsche Bank Trust Company Americas. You can contact Deutsche Bank broker services desk on +1 212 250 9100 or +44 207 547 6500
If you do not hold via a broker, bank or nominee, please contact our transfer agent:
Deutsche Bank Shareholder Services
American Stock Transfer & Trust Company
6201 15th Avenue
Brooklyn, NY 11219
Email: DB@amstock.com
Toll-free number: +1 866 249 2593
Direct Dial: +1 718 921 8137
For corporate action information, please visit:
Search for Anteris Technologies Ltd and then select Corporate Actions tab.
Alternatively you may contact Deutsche Bank Trust Company Americas Shareholder Services on toll-free number +1 866 249 2593 or direct dial +1 718 921 8137.
CONTACT U.S. INVESTOR RELATIONS
Malini Chatterjee, PhD. Managing Director
Blueprint Life Science Group
mchatterjee@bplifescience.com